Iadademstat
Iadademstat (ORY-1001) is a highly potent, orally active and selective LSD1 (KDM1A) inhibitor with antileukemic activity. Iadademstat can be used for relapsed or refractory acute myeloid leukemia research[1].
Product Specifications
CAS Number
1431304-21-0
Product Name Alternative
ORY-1001
UNSPSC
12352005
Target
Apoptosis; Histone Demethylase
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/iadademstat.html
Concentration
10mM
Purity
99.82
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
N[C@@H]1CC[C@@](CC1)([H])N[C@H]2[C@H](C3=CC=CC=C3)C2
Molecular Formula
C15H22N2
Molecular Weight
230.35
References & Citations
[1]Olga Salamero, et al. First-in-Human Phase I Study of Iadademstat (ORY-1001) : A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2020 Dec 20;38 (36) :4260-4273. |[2]Lu Z, et al., ORY-1001 Suppresses Cell Growth and Induces Apoptosis in Lung Cancer Through Triggering HK2 Mediated Warburg Effect. Front Pharmacol. 2018 Dec 4;9:1411.|[3]Yang H, et al., [ORY-1001 inhibits glioblastoma cell growth by downregulating the Notch/HES1 pathway via suppressing lysine-specific demethylase 1 expression]. Nan Fang Yi Ke Da Xue Xue Bao. 2024 Aug 20;44 (8) :1620-1630. Chinese.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
KDM1/LSD1
Citation 01
BioRxiv. 2025 Oct 15.|Cell Biosci. 2022 Aug 30;12 (1) :140|EMBO Mol Med. 2025 Aug 29.|J Appl Toxicol. 2023 Nov;43 (11) :1748-1760.|J Med Chem. 2024 Nov 14;67 (21) :19874-19888.|J Med Chem. 2025 May 8;68 (9) :9260-9278.|Oncogene. 2021 Apr;40 (15) :2711-2724.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
